Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 11/20 | 0.50 |
| ▸ | PPARA | Q07869 | 11/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991916 | 0.95 | PPARG (0.50) | KMT2APPARGPPARAGAANPSR1 | |
| SCHEMBL21991945 | 0.92 | HPGD (0.54) | KMT2APPARGPPARAGAANPSR1 | |
| SCHEMBL21992720 | 0.88 | FFAR1 (0.62) | KMT2APPARGPPARAFFAR1 | |
| SCHEMBL21991984 | 0.88 | FFAR1 (0.62) | KMT2APPARGPPARAFFAR1 | |
| SCHEMBL21991967 | 0.88 | FFAR1 (0.62) | KMT2APPARGPPARAFFAR1 | |
| SCHEMBL21991313 | 0.86 | L3MBTL1 (0.55) | KMT2APPARGPPARAFFAR1CYP2C9 | |
| SCHEMBL23606001 | 0.84 | L3MBTL1 (0.49) | KMT2APPARGPPARAGAANPSR1 | |
| SCHEMBL21991878 | 0.84 | MTNR1A (0.58) | KMT2APPARGPPARAFFAR1 | |
| SCHEMBL8480831 | 0.84 | MTNR1A (0.44) | KMT2AGAAFFAR1CYP1A2CYP2C9 | |
| SCHEMBL1418060 | 0.83 | MTNR1A (0.59) | KMT2AGAAFFAR1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
| CN-1015545-B | preparation method of glycolic acid derivative for treating diabetic complications | PFIZER (US) | 1992-02-19 | — | — | CN | disclosed |
| EP-0230379-B1 | CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4853410-A | Hydroxyacetic acid derivatives for the treatment of diabetic complications | PFIZER INC. (US) | 1989-08-01 | — | — | US | disclosed |
| CN-87100191-A | The hydroxy acid derivative of treatment diabetic complication | — | 1987-09-09 | — | — | CN | disclosed |
| WO-1987004344-A1 | HYDROXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885PPARG 1583/4885PPARA 806/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | KMT2A 4842/4885PPARG 1583/4885PPARA 806/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885PPARG 1583/4885PPARA 806/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885PPARG 1583/4885PPARA 806/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885PPARG 1583/4885PPARA 806/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885PPARG 1583/4885PPARA 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.